From what was relayed in Corporate updates at Sept AGM to current, Resverlogix and the Clinical Steering Committee have decided not to do the sample size re-estimation analysis and therefore no additional enrollment will be done. So from that perspective, there is no wiggle room on the Third Eye requirement for top-line by end of Jan 2019. If management doesn't discuss this issue, then this would be excellent question for Noretreat and others to ask who may be at Biotech Showcase in less than 2 weeks.

BDAZ